litlas
Log inCreate account

Hans Lennernäs

Active 1992–2025

109
Papers
18,858
Citations
70
h-index
104
i10-index

Citations

Citations per year for Hans Lennernäs1967: 1 citations1975: 1 citations1993: 2 citations1994: 3 citations1995: 17 citations1996: 36 citations1997: 48 citations1998: 67 citations1999: 67 citations2000: 72 citations2001: 112 citations2002: 89 citations2003: 117 citations2004: 124 citations2005: 144 citations2006: 161 citations2007: 239 citations2008: 171 citations2009: 193 citations2010: 217 citations2011: 166 citations2012: 209 citations2013: 245 citations2014: 209 citations2015: 132 citations2016: 158 citations2017: 112 citations2018: 108 citations2019: 408 citations2020: 517 citations2021: 446 citations2022: 287 citations2023: 240 citations2024: 387 citations2025: 188 citations2026: 6 citations1968–1974: no citations, so these years are not shown1976–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,157 citing papers, 19% of this breakdownUnited Kingdom: 507 citing papers, 8.3% of this breakdownGermany: 391 citing papers, 6.4% of this breakdownChina: 356 citing papers, 5.8% of this breakdownSweden: 316 citing papers, 5.2% of this breakdownIndia: 276 citing papers, 4.5% of this breakdownSwitzerland: 197 citing papers, 3.2% of this breakdownItaly: 183 citing papers, 3% of this breakdownJapan: 182 citing papers, 3% of this breakdownBelgium: 164 citing papers, 2.7% of this breakdownFrance: 144 citing papers, 2.4% of this breakdownNetherlands: 134 citing papers, 2.2% of this breakdown
0%19%Other 34.3%

Institutions

Fields

  • Pharmacology, Toxicology and Pharmaceutics33.3%
  • Medicine32.7%
  • Biochemistry, Genetics and Molecular Biology11.3%
  • Computer Science6.4%
  • Materials Science4.1%
  • Chemistry4.1%
  • Other8.1%

Topics

  • Drug Solubulity and Delivery Systems11.5%
  • Advanced Drug Delivery Systems6.4%
  • Drug Transport and Resistance Mechanisms5.6%
  • Computational Drug Discovery Methods4.3%
  • Analytical Chemistry and Chromatography3.8%
  • Crystallization and Solubility Studies3.4%
  • Other65%

Coauthors

All papers

Open in search
  1. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

    Authors: Gordon L. Amidon, Hans Lennernäs, Vinod P. Shah, John R. Crison - Pharmaceutical Research 1995 cited by 5,323

  2. Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches

    Authors: David Dahlgren, Hans Lennernäs - Pharmaceutics 2019 cited by 248

  3. Review on the effect of chemotherapy on the intestinal barrier: Epithelial permeability, mucus and bacterial translocation

    Authors: David Dahlgren, Hans Lennernäs - Biomedicine & Pharmacotherapy 2023 cited by 74

  4. Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies

    Authors: David Dahlgren, Markus Sjöblom, Per M. Hellström, Hans Lennernäs - Frontiers in Pharmacology 2021 cited by 134

  5. Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma

    Authors: Jaafar Khaled, Maria Kopsida, Hans Lennernäs, Femke Heindryckx - Cells 2022 cited by 75

  6. The Critical Role of Passive Permeability in Designing Successful Drugs

    Authors: Li Di, Per Artursson, Alex Avdeef, Leslie Z. Benet, J. Brian Houston, Manfred Kansy, Edward H. Kerns, Hans Lennernäs, Dennis A. Smith, Kiyohiko Sugano - ChemMedChem 2020 cited by 109

  7. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs

    Authors: Duxin Sun, Hans Lennernäs, Lynda S. Welage, Jeffery L. Barnett, Christopher P. Landowski, David R. Foster, David Fleisher, Kyung‐Dall Lee, Gordon L. Amidon - Pharmaceutical Research 2002 cited by 441

  8. Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification

    Authors: Nehal A. Kasim, Marc Whitehouse, Chandrasekharan Ramachandran, Marival Bermejo, Hans Lennernäs, Ajaz Hussain, Hans E. Junginger, Salomon Stavchansky, Kamal K. Midha, Vinod P. Shah, Gordon L. Amidon - Molecular Pharmaceutics 2003 cited by 844

  9. Inhibiting the endoplasmic reticulum stress response enhances the effect of doxorubicin by altering the lipid metabolism of liver cancer cells

    Authors: Maria Kopsida, Ada Lerma Clavero, Jaafar Khaled, David Balgoma, Clara Luna-Marco, Azazul Chowdhury, Sofi Sennefelt Nyman, Fredrik Rorsman, Charlotte Barbier, Peter Bergsten, Hans Lennernäs, Mikael Hedeland, Femke Heindryckx - Molecular Metabolism 2023 cited by 26

  10. Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review

    Authors: Joseph P. O’Shea, Patrick Augustijns, Martin Brandl, David J. Brayden, Joachim Brouwers, Brendan T. Griffin, René Holm, Ann-Christin Jacobsen, Hans Lennernäs, Zahari Vinarov, Caitríona M. O’Driscoll - European Journal of Pharmaceutical Sciences 2021 cited by 67

  11. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model

    Authors: Xianhua Cao, Seth Gibbs, Lanyan Fang, Heather A. Miller, Christopher P. Landowski, Ho‐Chul Shin, Hans Lennernäs, Yanqiang Zhong, Gordon L. Amidon, Lawrence X. Yu, Duxin Sun - Pharmaceutical Research 2006 cited by 385

  12. Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited

    Authors: Ahmad Al‐Saffar, Hans Lennernäs, Per M. Hellström - Neurogastroenterology & Motility 2019 cited by 93

  13. Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis Approach

    Authors: Susanne Winiwarter, Nicholas M. Bonham, Fredrik Ax, Anders Hallberg, Hans Lennernäs, Anders Karlén - Journal of Medicinal Chemistry 1998 cited by 452

  14. Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation

    Authors: Gudmundur Johannsson, A. G. Nilsson, Ragnhildur Bergthorsdottir, Pia Burman, Per Dahlqvist, Bertil Ekman, Britt Edén Engström, Tommy Olsson, Óskar Ragnarsson, Mats Ryberg, Jeanette Wahlberg, Beverly M. K. Biller, John P. Monson, Paul M. Stewart, Hans Lennernäs, Stanko Skrtic - The Journal of Clinical Endocrinology & Metabolism 2011 cited by 328

  15. Intestinal permeability and its relevance for absorption and elimination

    Authors: Hans Lennernäs - Xenobiotica 2007 cited by 295

  16. Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods

    Authors: David Dahlgren, Carl Roos, Erik Sjögren, Hans Lennernäs - Journal of Pharmaceutical Sciences 2014 cited by 123

  17. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma

    Authors: Charlotte Ebeling Barbier, Femke Heindryckx, Hans Lennernäs - International Journal of Molecular Sciences 2021 cited by 50

  18. Influence of extracellular matrix composition on tumour cell behaviour in a biomimetic in vitro model for hepatocellular carcinoma

    Authors: Carlemi Calitz, Jenny Rosenquist, Oliver Degerstedt, Jaafar Khaled, Maria Kopsida, Mårten Fryknäs, Hans Lennernäs, Ayan Samanta, Femke Heindryckx - Scientific Reports 2023 cited by 41

  19. ABSORPTION/METABOLISM OF SULFORAPHANE AND QUERCETIN, AND REGULATION OF PHASE II ENZYMES, IN HUMAN JEJUNUM IN VIVO

    Authors: Niclas Petri, Christer Tannergren, Birgit Holst, Fred A. Mellon, Yongping Bao, Geoff W. Plumb, Jim Bacon, Karen O’Leary, Paul A. Kroon, Lars Knutson, Patrik Forsell, Thomas Eriksson, Hans Lennernäs, Gary Williamson - Drug Metabolism and Disposition 2003 cited by 221

  20. In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma

    Authors: Fredrik Kullenberg, Oliver Degerstedt, Carlemi Calitz, Nataša Pavlović, David Balgoma, Johan Gråsjö, Erik Sjögren, Mikael Hedeland, Femke Heindryckx, Hans Lennernäs - Cells 2021 cited by 70

  21. In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects

    Authors: Erik Sjögren, Bertil Abrahamsson, Patrick Augustijns, D. E. Becker, Michael B. Bolger, Marcus E. Brewster, Joachim Brouwers, Talia Flanagan, Matthew D. Harwood, Christian Heinen, René Holm, Hans‐Paul Juretschke, Marlies Kubbinga, Anders Lindahl, Viera Lukáčová, Uwe Münster, Sibylle Neuhoff, Mai Anh Nguyen, Achiel Van Peer, Christos Reppas, Amin Rostami‐Hodjegan, Christer Tannergren, Werner Weitschies, Clive Wilson, Patricia Zane, Hans Lennernäs, Peter Langguth - European Journal of Pharmaceutical Sciences 2014 cited by 274

  22. The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids

    Authors: Eva Persson, Ann-Sofie Gustafsson, Anders S. Carlsson, Ralf Nilsson, Lars Knutson, Patrick Forsell, Gunilla Hanisch, Hans Lennernäs, Bertil Abrahamsson - Pharmaceutical Research 2005 cited by 264

  23. Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets

    Authors: Dag Nyholm, Håkan Askmark, Cecilia Gomes–Trolin, Tina W. Knutson, Hans Lennernäs, Christer Nyström, Sten‐Magnus Aquilonius - Clinical Neuropharmacology 2003 cited by 237

  24. Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women

    Authors: Anders Lindahl, Anna‐Lena Ungell, Lars Knutson, Hans Lennernäs - Pharmaceutical Research 1997 cited by 408